Breast Cancer Update

Featuring perspectives from Dr Aditya Bardia, Dr Kevin Kalinsky and Dr Joyce O'Shaughnessy, including the following topics:
Introduction (0:00)
Hormone Receptor-Positive Breast Cancer — Dr Kalinsky (1:18)
HER2-Positive Breast Cancer — Dr Bardia (42:46)
Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:01:41)

CME information and select publications

Featuring perspectives from Dr Lisa A Carey and Dr Maha Hussain, including the following topics:
Introduction (0:00)
HER2 History (1:32)
Cases from the GMO Survey (7:06)
Biology and Selection of First-Line Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer (mBC) — Dr Mahtani (19:56)
Faculty Case Presentations (31:37)
Patterns of Care Survey — Part 1 (38:26)
Optimizing the Use of Up-Front Maintenance Therapy for HER2-Positive mBC — Dr Carey (44:53)
Faculty Case Presentations (54:13)

CME information and select publications

Featuring perspectives from Prof Peter Schmid and Dr Melinda Telli, including the following topics:
Introduction: TROP2-Targeting Antibody-Drug Conjugates (ADCs) for Metastatic Triple-Negative Breast Cancer (0:00)
First-Line Therapy (PD-L1 Negative) (6:53)
First-Line Therapy (PD-L1 Positive) (23:40)
Second-Line Therapy (Sequencing) (34:08)
Adverse Events with TROP2-Targeting ADCs (43:43)

CME information and select publications

Featuring perspectives from Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics:
Introduction: San Antonio Memories (0:00)
PI3K/AKT/PTEN Alterations and Therapies (7:18)
Capivasertib (20:22)
Gedatolisib (34:08)
Inavolisib (47:07)
New Agents and Ongoing Trials (52:34)

CME information and select publications

Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics:
Introduction (0:00)
Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37)
Practical Considerations with Oral SERDs (15:43)
Potential Role of Combination Approaches with Oral SERDs (26:33)
Gastrointestinal Adverse Events Documented with Oral SERDs (38:19)
Potential Role of Early Therapeutic Switching After Detection of an Emergent ESR1 Mutation (46:54)
Other Class-Effect Toxicities Associated with Oral SERDs (1:00:56)
Emerging Utility of Adjuvant Oral SERDs (1:10:20)
Unique Toxicities Associated with 1 or More Oral SERDs (1:19:22)

CME information and select publications